{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 3 of 3 results
Status:
Possibly Marketed Outside US
Source:
Abanquil by Onbio Inc.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Abanoquil (UK-52,046), an antiarrhythmic drug, is an alpha 1-adrenoceptor antagonist, has been studied for the treatment of erectile dysfunction.
Status:
Possibly Marketed Outside US
Source:
ADBETA by Sepracor
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Esatenolol is the (S) enantiomer of atenolol, a beta1-adrenergic receptor antagonist. Only (S)-atenolol, but not (R)-atenolol, contributes to the beta-blocking effect of currently used racemic atenolol since the same effect can be elicited with the (S)-enantiomer alone. Pure (S)-atenolol has been launched in India for the treatment of hypertension and angina pectoris.
Status:
Possibly Marketed Outside US
Source:
Abanquil by Onbio Inc.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Abanoquil (UK-52,046), an antiarrhythmic drug, is an alpha 1-adrenoceptor antagonist, has been studied for the treatment of erectile dysfunction.
